Longevity & Aging
Does resveratrol switch on a longevity gene?
The claim, precisely: resveratrol activates SIRT1
Leans against Longevity & Aging 🐭 Non-human evidence🔬 Includes disconfirming
RefutedContestedStrong support
consensus score -0.56
Probably not — four independent labs showed the original finding was a lab-test quirk, only ever seen in the lab.
Evidence ladder
How far up the ladder this claim has climbed. A high consensus on a low rung means "consistent so far," not "proven in people."
Top evidence so far: Cells in a dish (In-vitro)
MechanismIn-vitroAnimalObservationalRCTMeta-analysis
How the studies fall
2 support 7 contradict 0 tested null 4 mixed · 13 sources, 8 independent groups
What the evidence shows
The origin claim (Howitz/Sinclair 2003). Decisively challenged as a Fluor-de-Lys fluorophore-substrate ASSAY ARTIFACT by four independent groups (Kaeberlein, Denu, Pfizer, GSK) - resveratrol is not a direct activator of SIRT1 with native substrates.
The evidence (13)
| Source | Grade | Stance | Quality | Finding |
|---|---|---|---|---|
| Dai 2010 · J Biol Chem | in-vitro | mixed | moderate | Kinetic/biophysical evidence for direct STAC-SIRT1 interaction; activation seen but substrate/fluorophore dependence acknowledged |
| Manna 2018 · J Mol Model | mechanism | supports | low | Computational study models direct dihydropyridine/STAC binding driving SIRT1 conformational activation - mechanistic support for direct activation |
| Hubbard 2013 · Science | in-vitro | contradicts | high | Identifies SIRT1 Glu230 allosteric site; STACs activate SIRT1 with specific hydrophobic substrate motifs (e.g. PGC-1a) - not pure assay artifact |
| Howitz 2003 · Nature | in-vitro | supports | moderate | Origin claim: resveratrol lowers SIRT1 Km, stimulates p53 deacetylation, extends yeast lifespan 70% |
| Fiorentino 2025 · Med Res Rev | mechanism | mixed | moderate | Review concludes resveratrol is a genuine but weak, substrate-selective SIRT1 activator - reconciles artifact critique with allosteric evidence |
| Cao 2015 · Genes Dev | in-vitro | contradicts | high | Crystal structure: three resveratrol molecules mediate SIRT1 N-terminal binding to a coumarin peptide - structural basis for substrate-dependent activation |
| Nguyen 2013 · Chem Biol | in-vitro | mixed | moderate | Crystal structures show 4'-bromo-resveratrol binds two SIRT3 sites; supports an allosteric site model relevant to SIRT1 activation |
| Kaeberlein 2005 · J Biol Chem | in-vitro | contradicts | high | Resveratrol activates Sir2/SIRT1 only on Fluor-de-Lys fluorophore-tagged peptides; no in-vivo Sir2 effect in 3 yeast backgrounds |
| Borra 2005 · J Biol Chem | in-vitro | contradicts | high | [FT-verified] Borra: ~8x activation only with covalently-attached fluorophore - the artifact source |
| Beher 2009 · Chem Biol Drug Des | in-vitro | contradicts | high | [FT-verified] Beher: Fluor-de-Lys artificial substrate, no activation on p53 peptide |
| Gertz 2012 · PLoS One | in-vitro | mixed | moderate | Resveratrol directly modulates sirtuins (activates SIRT1/SIRT5, inhibits SIRT3) via a fluorophore-dependent mechanism - effect is substrate-conditional |
| Pacholec 2010 · J Biol Chem | in-vitro | contradicts | high | [FT-verified] Pacholec: resveratrol+SRT1720 fail to activate SIRT1 with native substrate |
| Dai 2015 · Nat Commun | in-vitro | contradicts | high | Crystal structure of mini-hSIRT1-STAC complex shows direct activator binding to the N-terminal domain - direct activation mechanism, not artifact |
Educational only, not medical advice. Grades and scores reflect published evidence weighted by study design and quality; see the methodology.